It's The 1950's Again!

“The price is what you pay, Value is what you get” ― Warren Buffett The Portfolio Our blog portfolio continues to perform well and volatility remains low. Year-To-Date the portfolio is up +15.21% (as I write, markets are still open). While I think the stock market is fairly valued (not cheap or expensive), I'm not adding anything today, I prefer to wait for pull backs. The Fed Fed Chairman Jerome Powell delivered a highly anticipated speech yesterday...where he gave the markets everything they wanted,no change to current short-term rates. My position remains the same, I think the Fed will lower rates 1-2 times this year. The biggest concern over lower rates is heard in this often repeate

Paper or Plastic?

“Go for a business that any idiot can run – because sooner or later any idiot probably is going to be running it.” ― Peter Lynch The Portfolio Our blog portfolio continues to perform well and volatility remains low. Year-To-Date the portfolio is up +13.73% (as I write, markets are still open). Today I added to some of our existing positions where prices were below our cost basis. New Subscribers Several new subscribers joined the blog today. Thank you all for joining and participating. I always enjoy hearing from subscribers and like getting readers suggestions for new posts. Today's Buys CVS 24 shares @ $54.41; total holding = 100 (cost basis reduced from $56.65 to $56.05) BSTC 25 shar

An All-Weather Portfolio?

“Go for a business that any idiot can run – because sooner or later any idiot probably is going to be running it.” ― Peter Lynch The Portfolio Our blog portfolio is turning out to be an all-weather performer. Year-To-Date the portfolio is up +13.39% and we still have $46,000 in cash to invest. With the S&P 500 up 13.43%. I suspect when the rest of the cash is put to work we'll see better performance. Keep in mind that the long term average for the S&P 500 is about 10%, so we've done well and so has the index. Looking at some of our stocks Within the portfolio we have four stocks that are negative and 23 that are positive. Our biggest loser is Nabriva Therapeutics (NBRV), a high risk/rew

Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • LinkedIn Social Icon
  • Google+ Social Icon
  • Twitter Social Icon
  • Facebook Social Icon

This material is provided for informational purposes only, as of the date hereof, and is subject to change without notice.
This material may not be suitable for all investors and is not intended to be an offer, or the solicitation of any offer, to buy or sell any securities.

© 2016 by Clay Baker all rights reserved